IN8bio Inc
INAB
Company Profile
Business description
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Contact
350 5th Avenue
Suite 5330
New YorkNY10118
USAT: +1 646 600-6438
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
ASX listed gold miner under pressure due to lower production
Shares have dropped nearly 20% since lowering 2026 volume guidance.
stocks
3 ASX opportunities after earnings season
Uncovering key opportunities following February’s results.
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
We raise our fair value estimate for Oracle stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,790.60 | 38.10 | -0.43% |
| CAC 40 | 7,935.97 | 24.44 | 0.31% |
| DAX 40 | 23,564.01 | 116.72 | 0.50% |
| Dow JONES (US) | 46,946.41 | 387.94 | 0.83% |
| FTSE 100 | 10,317.69 | 56.54 | 0.55% |
| HKSE | 26,123.96 | 289.94 | 1.12% |
| NASDAQ | 22,374.18 | 268.82 | 1.22% |
| Nikkei 225 | 54,013.73 | 262.58 | 0.49% |
| NZX 50 Index | 13,144.82 | 19.76 | -0.15% |
| S&P 500 | 6,699.38 | 67.19 | 1.01% |
| S&P/ASX 200 | 8,585.90 | 32.80 | -0.38% |
| SSE Composite Index | 4,097.19 | 12.40 | 0.30% |